PEPG — PepGen Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1835597 ·
Last close
$2.34
Market Cap
$161.86M
52W High
$2.44
52W Low
$1.31
ADV30
793,113
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -18,942,000 | -17,763,000 | 156,295,000 | 42,150,000 | 22,315,000 |
| Dec 2025 | 0 | — | -19,705,000 | -18,340,000 | 173,907,000 | 60,514,000 | 26,463,000 |
| Sep 2025 | 0 | — | -18,654,000 | -18,026,000 | 190,057,000 | 142,775,000 | 26,917,000 |
| Jun 2025 | 0 | — | -23,932,000 | -23,087,000 | 102,242,000 | 35,072,000 | 31,084,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-77,131,000
Investing CF
$-33,843,000
Financing CF
$109,497,000
CapEx
$-493,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.75
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-378,881,000
Inventory
—
Receivables
—
ST Investments
$90,153,000
EBIT TTM
$-81,233,000
Pretax Income TTM
$-77,152,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -93,612,000 | -89,655,000 | 173,907,000 | 26,463,000 | — | -81,635,000 |
| Dec 2024 | 0 | -97,739,000 | -89,981,000 | 150,883,000 | 32,263,000 | — | -82,372,000 |
| Dec 2023 | 0 | -84,766,000 | -78,626,000 | 143,052,000 | 34,631,000 | — | -68,997,000 |
| Dec 2022 | 0 | -68,301,000 | -69,104,000 | 217,440,000 | 37,809,000 | — | -59,265,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | $162.07M | $4.50 | — |
| MENS | Jyong Biotech Ltd. | $164.06M | $2.21 | — |
| ADCT | ADC Therapeutics SA | $164.08M | $1.29 | — |
| MIST | Milestone Pharmaceuticals Inc. | $159.36M | $1.28 | — |
| SMNR | Semnur Pharmaceuticals, Inc. | $158.84M | $0.69 | — |
News headlines (Yahoo Finance, 1h cache)
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-05-20 13:35 · Yahoo
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?
2026-05-18 04:49 · Yahoo
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
2026-05-13 16:00 · Yahoo
AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer
2026-05-12 07:30 · Yahoo
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway
2026-04-01 00:07 · Yahoo
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA
2026-03-05 10:59 · Yahoo
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44%
2025-12-10 14:55 · Yahoo
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
2025-11-25 18:08 · Yahoo
PepGen Inc.'s (NASDAQ:PEPG) largest shareholders are individual investors with 39% ownership, private equity firms own 36%
2025-11-15 12:53 · Yahoo
BofA Lifts PepGen (PEPG) PT to $3 on Positive DM1 Data Despite Underperform Rating
2025-10-26 10:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.